The federal contract IDV SPE2D221D0130 is a single-award indefinite delivery contract awarded to Radha Pharmaceuticals Inc., a minority-owned small disadvantaged business. The $15.9 million contract has a period of performance through June 20, 2026 and was issued by the Defense Logistics Agency Troop Support Medical, a component of the Department of Defense.
The contract aims to establish a national supply source for several high-volume pharmaceutical products including gabapentin, atorvastatin calcium, clopidogrel bisulfate, fluoxetine hydrochloride, bupropion HCL ER, naproxen, hydralazine, and celecoxib in various strengths and packaging configurations. These brand-name and generic drug products will be supplied to government customers such as the VA, DoD, Bureau of Prisons, and Indian Health Service through the VA and DLA pharmaceutical prime vendor programs. The IDV utilizes firm-fixed pricing with a one-year base period and multiple option years to provide an uninterrupted supply of these medications to fulfill estimated annual requirements of over 200,000 units.
Generated 8/30/24, 6:21 PM